Femara, Letrozole Newswire

Femara, Letrozole Newswire

Comprehensive Real-Time News Feed for Femara, Letrozole (generic).

Results 1 - 20 of 23 in Femara, Letrozole (generic)

  1. Global Letrozole (CAS 112809-51-5) Market 2016 - Novartis, Shilpa...Read the original story w/Photo

    Jan 11, 2017 | SBWire

    Letrozole is an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery. This report provides detailed analysis of worldwide markets for Letrozole from 2011-2015 and provides extensive market forecasts 2016-2021 by region/country and subsectors.

    Comment?

  2. Survivor of the YearRead the original story w/Photo

    Jan 7, 2017 | Manchester Journal

    Newly named the Komen VT-NH Affiliate's Survivor of the Year for 2007, Kerry Clifford, of Brandon, has competed in the Komen Race for the Cure held at Hildene Meadows in Manchester for ten out of the past 11 years. She has consistently finished in the 5K Walk's Overall Top 35, with her best Overall Walker finish in 7th place in 1999 and finished the 5K Walk as one of the top-4 breast cancer survivors in all ten Komen races she has taken part in.

    Comment?

  3. FDA accepts Pfizer's marketing application for expanded use of breast ...Read the original story w/Photo

    Dec 21, 2016 | Seeking Alpha

    The FDA accepts for review Pfizer's supplemental New Drug Application seeking approval for the use of IBRANCE , in combination with letrozole, to treat postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. The application includes data from the Phase 3 PALOMA-2 study which was conducted in the same patient population as the Phase 2 PALOMA-1 trial, the basis for accelerated approval status granted by the FDA in February 2015.

    Comment?

  4. Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for...Read the original story w/Photo

    Dec 14, 2016 | PR Newswire

    Report Details Breast Cancer Therapies - Discover From 2016 What Revenues Are Possible Are you interested in the breast cancer drug market's future? If so, you find that sales forecasting from 2016 in our new report. See there what is possible for those products and companies.

    Comment?

  5. Certain Breast Cancer Drugs Tied to Blood Vessel DamageRead the original story w/Photo

    Dec 9, 2016 | MedicineNet

    Women on breast cancer drugs called aromatase inhibitors may show signs of early blood vessel damage that could lead to heart disease , a small study suggests. Researchers found that compared with healthy women their age, women on aromatase inhibitors were more likely to show signs of "endothelial dysfunction."

    Comment?

  6. Certain breast cancer drugs tied to blood vessel damageRead the original story w/Photo

    Dec 9, 2016 | PhysOrg Weblog

    Women on breast cancer drugs called aromatase inhibitors may show signs of early blood vessel damage that could lead to heart disease, a small study suggests. Researchers found that compared with healthy women their age, women on aromatase inhibitors were more likely to show signs of "endothelial dysfunction."

    Comment?

  7. Taking Breast Cancer Prevention Drug Beyond 5 Years May Not Raise SurvivalRead the original story w/Photo

    Dec 7, 2016 | MedicineNet

    Many breast cancer survivors take anti-estrogen drugs for at least five years to help lessen their risk of recurrence. Now, new research suggests that taking such a drug for an even longer period might not confer any added benefit -- at least in terms of survival.

    Comment?

  8. Most common fertility treatments: how they work and how much they costRead the original story w/Photo

    Dec 1, 2016 | GlobalNews

    It took Rebecca Nielsen, the wife of a Global News employee, a lot of fertility treatments to become a mom last fall. The 41-year-old and her husband met in 2009.

    Comment?

  9. New drug may brighten outlook for advanced breast cancerRead the original story w/Photo

    Nov 18, 2016 | Chicago Tribune

    The drug, called palbociclib , was approved in the United States last year for treating advanced cases of ER-positive breast cancer. That means the cancer uses the hormone estrogen to help fuel its growth.

    Comment?

  10. New Drug May Brighten Outlook for Advanced Breast CancerRead the original story w/Photo

    Nov 17, 2016 | MedicineNet

    The drug, called palbociclib , was approved in the United States last year for treating advanced cases of ER-positive breast cancer . That means the cancer uses the hormone estrogen to help fuel its growth.

    Comment?

  11. Drug can help slow advanced breast cancerRead the original story w/Photo

    Nov 17, 2016 | CBS News

    The drug, called palbociclib , was approved in the United States last year for treating advanced cases of ER-positive breast cancer. That means the cancer uses the hormone estrogen to help fuel its growth.

    Comment?

  12. Novartis Takes Aim at PfizerRead the original story w/Photo

    Nov 3, 2016 | Fox News

    The priority-review timeline accelerates a decision to six months from 10 months, meaning that an official go/no-go decision from the FDA could be on tap next spring. If approved, ribociclib could challenge Pfizer 's Novartis is seeking approval of ribociclib for use alongside letrozole , a drug used to stop estrogen production, as a front-line treatment for postmenopausal women who are diagnosed with HR+ , HER2- , advanced/metastatic breast cancer.

    Comment?

  13. Novartis Takes Aim at PfizerRead the original story w/Photo

    Nov 3, 2016 | The Motley Fool

    Novartis is closing in on the finish line with a new breast cancer drug that, if approved, could compete for market share with Pfizer's Ibrance. application for FDA approval of ribociclib for first-line use alongside letrozole, in patients who have advanced breast cancer with an amenable genetic makeup, has been accepted by regulators under priority review.

    Comment?

  14. Novartis AG (ADR) (NVS) And Pfizer Inc. (PFE) Are In A Race To Gain Favor In Breast CancerRead the original story w/Photo

    Nov 2, 2016 | Insider Monkey

    Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages. We only allow registered users to use ad blockers.

    Comment?

  15. Novartis' LEE011 beats standard-of-care treatment in late-stage...Read the original story w/Photo

    Oct 8, 2016 | Seeking Alpha

    Interim results from a Phase 3 clinical trial, MONALEESA-2, evaluating Novartis' LEE011 for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced/metastatic breast cancer demonstrated superiority over standard-of-care treatment. The data were presented today at the European Society for Medical Oncology 2016 Congress in Copenhagen and published simultaneously online in The New England Journal of Medicine.

    Comment?

  16. Diagnosis and Treatment of Polycystic Ovary SyndromeRead the original story

    Jul 15, 2016 | American Academy of Family Physicians

    Polycystic ovary syndrome is the most common endocrinopathy among reproductive-aged women in the United States, affecting approximately 7% of female patients. Although the pathophysiology of the syndrome is complex and there is no single defect from which it is known to result, it is hypothesized that insulin resistance is a key factor.

    Comment?

  17. Study tests new breast cancer drug in African American womenRead the original story w/Photo

    Jul 6, 2016 | PhysOrg Weblog

    The first clinical trial to test a newly approved breast cancer drug specifically in African American patients is now enrolling at Georgetown Lombardi Comprehensive Cancer Center and will begin soon at five other institutions in Washington, DC, Maryland, Alabama and New Jersey. The phase II study will evaluate the safety of palbociclib in African American patients , including those who may have a low white blood cell count due to "benign ethnic neutropenia."

    Comment?

  18. Smoking May Hinder Common Breast Cancer TreatmentRead the original story w/Photo

    Jun 27, 2016 | News Max

    Smoking may blunt the effectiveness of a certain kind of breast cancer treatment, new research suggests. Among breast cancer patients taking a class of drugs called aromatase inhibitors, smokers had a three times greater risk of their cancer returning than nonsmokers, the investigators found.

    Comment?

  19. Fears raised over cost of breakthrough breast cancer drugRead the original story w/Photo

    Jun 8, 2016 | Halesowennews.co.uk

    Thousands of British women with advanced breast cancer may be denied a drug that can keep the disease in check, campaigners fear. Research presented at the world's biggest cancer conference in Chicago showed that women taking Ibrance with another common drug lived almost twice as long without their cancer getting worse as those given standard treatment.

    Comment?

  20. Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for...Read the original story w/Photo

    Jun 7, 2016 | PR Newswire

    Breast Cancer Therapies - Discover From 2016 What Revenues Are Possible Are you interested in the breast cancer drug market's future? If so, you find that sales forecasting from 2016 in our new report. See there what is possible for those products and companies.

    Comment?